2-(2,2-diethoxyethoxy)-5-fluorobenzaldehyde | 179728-59-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(2,2-diethoxyethoxy)-5-fluorobenzaldehyde
• 英文别名: 5-fluoro-2-(2,2-diethoxyethoxy)benzaldehyde
• CAS: 179728-59-7
• 化学式: C₁₃H₁₇FO₄
• 分子量: 256.274
• InChiKey: XTMCRBIQTPXGKJ-UHFFFAOYSA-N

物化性质

• 沸点：
  354.0±42.0 °C(Predicted)
• 密度：
  1.139±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2,2-diethoxyethoxy)-5-fluorobenzaldehyde 在 溶剂黄146 作用下， 生成 5-氟苯并呋喃-2-甲醛
  参考文献：
  名称：

  三唑促进乙烯基苯并呋喃的铁催化 C−H 烷基化/开环

  摘要：

  前所未有的 C(sp 2 )−O 断裂通过多功能的 CH/C−O/N−H 官能化级联实现了 2-乙烯基苯并呋喃的环化。该反应是使用肽等排三唑和廉价、无毒的铁催化剂实现的。

  DOI：

  10.1002/anie.202404319
• 作为产物：
  描述：

  4-氟苯酚 在 sodium hydroxide 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 2-(2,2-diethoxyethoxy)-5-fluorobenzaldehyde
  参考文献：
  名称：

  3-Benzo[b]furyl- and 3-benzo[b]thienylaminobutyric acids as GABAB ligands. Synthesis and structure-activity relationship studies

  摘要：

  Baclofen (beta-p-chlorophenyl GABA) is one of the selective agonists for the bicuculline-insensitive GABA(B) receptors. In the search for new compounds that bind to GABA(B) receptors it is very important to clarify the structural requirements. We report the syntheses of and binding studies on various S-heteroaromatic (benzo[b]furan and benzo[b]thiophen)aminobutyric acids. The 4-amino-3-(7-methyl-benzo[b]furan-2-yl)butanoic acid 8g is a potent and specific ligand for GABA(B) receptors, with an IC50 value of 5.4 mu M in the displacement of [H-3]GABA.

  DOI：

  10.1016/0223-5234(96)85165-8

文献信息

• [EN] TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS<br/>[FR] TRAITEMENT OU PROPHYLAXIE D'ÉTATS PROLIFÉRATIFS
  申请人：UNIV DUNDEE

  公开号：WO2010125350A1

  公开（公告）日：2010-11-04

  The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

  该发明涉及用于治疗或预防癌症和其他增殖性疾病的新化合物，例如这些疾病的特征是细胞表达细胞色素P450 1B1（CYP1B1）及其等位基因变体。该发明还提供包含一种或多种此类化合物的药物组合物，用于医学治疗，例如用于治疗或预防癌症或其他增殖性疾病，以及用于治疗人类或非人类动物患者的癌症或其他疾病的方法。该发明还提供用于识别用于治疗或预防癌症和其他增殖性疾病的新化合物的方法，例如这些疾病的特征是细胞表达CYP1B1及其等位基因变体。该发明还提供一种用于确定该发明中化合物治疗癌症的疗效的方法。
• [EN] PYRROLIDINE COMPOUNDS FOR THE TREATMENT OF MALARIA<br/>[FR] COMPOSÉS DE PYRROLIDINE POUR LE TRAITEMENT DU PALUDISME
  申请人：LEGION PHARMA CO LTD

  公开号：WO2020107189A1

  公开（公告）日：2020-06-04

  Pyrrolidine derivatives of formula I are used as anti-malaria agents, wherein the variables are as defined herein. Method of employing such agents in the treatment and prevention of malaria are also provided herein.

  Pyrrolidine衍生物的化学式I被用作抗疟疾药物，其中变量如本文所定义。本文还提供了在治疗和预防疟疾中使用这些药物的方法。
• Treatment or prophylaxis of proliferative conditions
  申请人：The University of the University of Dundee

  公开号：US08283340B2

  公开（公告）日：2012-10-09

  The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer.

  本公开涉及新型化合物的使用，用于治疗或预防癌症和其他增生性疾病，例如其特征为表达细胞色素P450 1B1（CYP1B1）及其等位基因变异体的细胞。还提供了包含一种或多种这样的化合物的药物组合物，用于医学治疗，例如用于治疗或预防癌症或其他增生性疾病，以及用于治疗人类或非人类动物患者的癌症或其他疾病的方法。提供了用于寻找用于治疗或预防表达CYP1B1及其等位基因变异体的细胞的癌症和其他增生性疾病的新型化合物的方法。最后，提供了一种确定本文所述化合物在治疗癌症方面的疗效的方法。
• TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS
  申请人：Everett Steven Albert

  公开号：US20120190639A1

  公开（公告）日：2012-07-26

  The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

  本发明涉及新型化合物，用于治疗或预防癌症和其他增生性疾病，例如其细胞表达细胞色素P450 1B1（CYP1B1）及其等位基因变异的疾病。本发明还提供了含有一种或多种这样的化合物的制药组合物，用于医学治疗，例如治疗癌症或其他增生性疾病的预防或治疗，以及用于治疗人类或非人类动物患者的癌症或其他疾病的方法。本发明还提供用于鉴定用于治疗或预防表达CYP1B1及其等位基因变异的细胞的癌症和其他增生性疾病的新型化合物的方法。本发明还提供了一种用于确定本发明的化合物在治疗癌症方面的功效的方法。
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：AQUINNAH PHARMACEUTICALS INC

  公开号：WO2018119395A8

  公开（公告）日：2019-05-23